Home
About
Overview
Sharing Data
ORCID
Help
History (26)
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
The next targets for small cell lung cancer.
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
See All 26 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol. 2018 10; 41(10):963-966.
View in:
PubMed
subject areas
Aged
Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Celecoxib
Female
Follow-Up Studies
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Survival Rate
Thymus Neoplasms
authors with profiles
Ravi Salgia